ZALTRAP Special Drug Use Surveillance (Unresectable advanced and/or recurrent colorectal cancer)
Not Applicable
- Conditions
- colorectal cancer
- Registration Number
- JPRN-UMIN000028897
- Lead Sponsor
- Sanofi K.K.
- Brief Summary
The incidence of adverse reactions in this study was lower than that occurred at the time of approval of the drug.The benefit-risk assessment of Zaltrap in this study was favorable and it was judged that there was no additional safety concerns identified.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 261
Inclusion Criteria
Not provided
Exclusion Criteria
Patients concurrently participating in any interventional clinical studies
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety: Incidence rate of adverse drug reaction Effectiveness: Tumor assessment
- Secondary Outcome Measures
Name Time Method